In the framework of the global strategy against acute hepatitis it is planned to significantly reduce morbidity and mortality. This at a press conference... 2019 interferonalfa therapy for hepatitis C may become a “thing of the past”

In the framework of the global strategy against acute hepatitis it is planned to significantly reduce morbidity and mortality. This at a press conference timed to the world day against hepatitis, said the chief hepatologist of the Ministry of health of the Moscow region, the head of Hepatology Department GBUZ MO MONIKI. M. F. Vladimirsky, Pavel Bogomolov.

So, by 2020, the aim is to reduce the incidence of 30, and the mortality rate is 10%. Similar indicators of decline to 2030 are respectively 90% and 65%.

The speaker talked about the experience of holding in the Moscow region large-scale antiviral therapy of hepatitis C in the framework of the Program of state guarantees of free medical assistance, including the use of innovative technologies of quality control of treatment.

So, a number of patients got access to antiviral therapy of hepatitis C in the framework of the program on risk sharing, which was implemented with the company “Biocad.” “The basis was taken model of risk-sharing, implemented in Italy – rasskazal Mr. Bogomolov. – If innovative treatment was deemed successful, the state pays the company the cost of LP, and if unsuccessful, the money the pharmaceutical manufacturer has not received”. Cure was achieved in 77.8% of cases. A relatively small amount of 5 million virtually any. for untreated patients, the manufacturer has less.

According to the representative of GBUZ MO MONICA, reached a preliminary agreement on cooperation in the framework of the project on risk sharing with foreign pharmaceutical manufacturer: “This product with incredible efficiency 95% cure, the model of risk sharing will be in this case more fashion value, and we can only marvel at the results.” Even more effective in his opinion, would be the introduction of system of medicinal insurance, however, today “the country is not ready for it”.

“We consistently from one year to treat hepatitis With nearly a thousand patients in the Moscow region, told the chief hepatologist of the Moscow region Ministry of health. Mass antiviral therapy continues in 2008, this year, the report to the Minister of health, I’ll write that the problem with the second and third genotypes of hepatitis C in the Moscow region is determined.”

One of the main tasks today is the transfer to the IFN-free therapy. “This year will be registered drugs, of the user which will be written the appointment in paediatric practice, – said Pavel Bogomolov. – First in Russia initiated interferon-free therapy in adolescents with chronic hepatitis C”.

In 2019 interferonbeta therapy will likely become a thing of the past, said the chief by a hematologist at Ministry of health of the region. This applies to patients of different categories, including patients with hemophilia.

“Two years ago it was impossible to imagine that almost 40% of patients with hemophilia will receive bezinteresno therapy from hepatitis C, told participating in

the press conference, the President of the Russian society of hemophilia, co-chair of the all-Russian Union of patient associations Yury Zhulev.

Praised the work of colleagues in the region head of Department of hospital therapy, Russian national research medical University them. N. And. Pirogov, Russia’s leading hepatologist Igor Nikitin. “Moscow region is the best region of the country from the point of view of the organization and providing medical aid to patients with acute hepatitis, he said. Here it all came together. It is the responsibility of the organizers and healthcare professionals and all the necessary infrastructure”.

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *